News | February 16, 2022
Mankind Pharma acquires two brands from Dr Reddy’s
The entire integration and transition of the brands is expected to be completed by March 2022
The entire integration and transition of the brands is expected to be completed by March 2022
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The service has already been initiated in Maharashtra but being net-based it is easily available for patients all across the country
It will open new frontier for south-to-south collaboration and innovation transfer
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
Dr. Reddy’s to promote and distribute select Novartis products including the Voveran range, the Calcium range and Methergine in India
Subscribe To Our Newsletter & Stay Updated
